Видео ютуба по тегу Refractory Cll

EPCORE CLL-1 trial: evaluating epcoritamab in patients with R/R CLL
EPCORE CLL-1 trial: evaluating epcoritamab in patients with R/R CLL
Crafting Custom Care in CLL
Crafting Custom Care in CLL
EPCORE CLL-1: An Advance in Treating Relapsed/Refractory Chronic Lymphocytic Leukemia
EPCORE CLL-1: An Advance in Treating Relapsed/Refractory Chronic Lymphocytic Leukemia
A Unique BTK Inhibitor, Pirtobrutinib for Patients with Pretreated CLL | Jeff Sharman, MD | #ASH24
A Unique BTK Inhibitor, Pirtobrutinib for Patients with Pretreated CLL | Jeff Sharman, MD | #ASH24
Duvelisib + Venetoclax: A Time-Limited, All Oral Option for CLL | Jennifer Crombie, MD | #ASH24
Duvelisib + Venetoclax: A Time-Limited, All Oral Option for CLL | Jennifer Crombie, MD | #ASH24
Solid Results for Epcoritimab for Relapsed / Refractory CLL - Dr. Arnon Kater
Solid Results for Epcoritimab for Relapsed / Refractory CLL - Dr. Arnon Kater
Ravi Vij, in Discussion with Dr. Ryan Jacobs MD, On Double Refractory CLL Treatment
Ravi Vij, in Discussion with Dr. Ryan Jacobs MD, On Double Refractory CLL Treatment
Ravi Vij, in Discussion with Dr. Ryan Jacobs MD, On Double Refractory CLL Treatment
Ravi Vij, in Discussion with Dr. Ryan Jacobs MD, On Double Refractory CLL Treatment
BTK Degrader Offers Promise in Relapsed and Refractory CLL
BTK Degrader Offers Promise in Relapsed and Refractory CLL
CAR T-cells and bispecific antibodies in the treatment of double refractory CLL
CAR T-cells and bispecific antibodies in the treatment of double refractory CLL
The VENICE-1 trial: venetoclax monotherapy in R/R CLL
The VENICE-1 trial: venetoclax monotherapy in R/R CLL
BTK Degrader Demonstrates Safety for Relapsed and Refractory CLL
BTK Degrader Demonstrates Safety for Relapsed and Refractory CLL
Sonrotoclax Plus Zanubrutinib Shows Deep Response in CLL
Sonrotoclax Plus Zanubrutinib Shows Deep Response in CLL
Increased Fatigue May Predict CLL Disease Progression
Increased Fatigue May Predict CLL Disease Progression
Combination Pirtobrutinib, Venetoclax, and Rituximab for CLL - Dr. Lindsey Roeker ASH 2023
Combination Pirtobrutinib, Venetoclax, and Rituximab for CLL - Dr. Lindsey Roeker ASH 2023
Ravi Vij, in Discussion with Dr. Marc S. Hoffmann MD, On Chronic Lymphocytic Leukemia(CLL) Treatment
Ravi Vij, in Discussion with Dr. Marc S. Hoffmann MD, On Chronic Lymphocytic Leukemia(CLL) Treatment
Chronic Lymphocytic Leukaemia (CLL) - New Study Results
Chronic Lymphocytic Leukaemia (CLL) - New Study Results
Overcoming Disease Progression in CLL: Evidence-Based Re-treatment Considerations
Overcoming Disease Progression in CLL: Evidence-Based Re-treatment Considerations
The Challenge of BCL-2 Resistance in CLL: Treatment Strategies and Emerging Therapies
The Challenge of BCL-2 Resistance in CLL: Treatment Strategies and Emerging Therapies
Mutational Testing to Guide Therapy in CLL: Why and When
Mutational Testing to Guide Therapy in CLL: Why and When